Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the
Launched Niagen™ Plus Niagen™ Liquid At-Home Injections
Launched Niagen NanoCloud™, the first dermatologist-tested topical product
Launched "Don’t Get Old. Age Better.®," a new brand campaign
Net sales of
Liquid formulation of Niagen™ Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin
Niagen Bioscience, Inc.
Following a customer-favorite limited release, Niagen NanoCloud™ debuts the Tru Niagen® Skincare category with a first-of-its-kind waterless, precision-dosed sachet technology that keeps Niagen’s benefits protected
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday,
This award recognizes Dr. Shao’s dedication to advancing NAD+ research and scientific excellence responsibly within the dietary supplement industry
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the 20th
The campaign pairs a new perspective on aging with the Company’s 25+ years of quality and scientific leadership, including over 45 peer-reviewed published clinical studies on its flagship precursor ingredient Niagen®
Proposed multi-year, randomized, placebo-controlled prevention trial would evaluate Niagen (patented nicotinamide riboside, or NR) supplementation across major clinical outcomes and healthy aging-related measures in
Preclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and inflammation, leads to NAD+ depletion in placental tissue, while restoring NAD+ with the precursor NR improved placental,
Advisors bring biotechnology fundraising, drug development, and commercialization, as well as corporate strategy and M&A expertise to support the advancement of NB4168 and strategic corporate growth
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq
Leading NAD+ healthy aging supplement reaches new health-conscious consumers at nearly 300 GNC and Sam’s Club locations across 44 states combined
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+
